Bullish & Foolish
Full SNTI fundamentals All 466 on the Survival Watch

SNTISenti Biosciences Holdings, Inc.

Is Senti Biosciences Holdings struggling financially?

Yes, by its own account. Senti Biosciences Holdings told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$12.1M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 1month

    If the burn speeds up

    Empty by Jul 2026

  • 3months

    If it eases off

    Empty by Sep 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$6.5M

÷

Cash burned over the last 12 months

$43.6M

What Senti Biosciences Holdings told the SEC

…future as the Company advances its preclinical activities and clinical trials for its product candidates in development. The Company concluded that substantial doubt continued to exist and that the Company’s cash and cash equivalents of $ 8.9 million as of March 31, 2026, were not sufficient for the Company to continue as a going concern for at least one year from the issuance date of these condensed consolidated financial statemen ts. Based on the Company’s current operating plan and existing unrestricted cash and…

Senti Biosciences Holdings, Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 71.7% share-count increase The company issued stock. Each share now owns 41.8% less of the business than a year ago, before any change in the price.
  • Debt pressure is material Debt is large against the cash on hand while the business generates little to service it, which puts lenders ahead of shareholders in the queue.
  • Cash burn is narrowing It is spending 47% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt